A recent study published in The New England Journal of Medicine investigated the potential use of gene editing to correct a congenital retinal degeneration called CEP290 that causes early-onset vision loss.
After patient outcry, Taysha starts to offload drug programs
Taysha Gene Therapies has offloaded some of the paused drugs in its pipeline, following nearly two years of pressure from patient groups who funded early
February 17, 2024